Reconstruction of the RVOT with valved biological conduits: 25 years experience with allografts and xenografts✩
| Autor: | Hans Meisner, Klaus Holper, Sung Un Paek, Michael Homann, John Cristoph Haehnel, Nikolaus Mendler, Rüdiger Lange |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Graft Rejection Heart Defects Congenital Male Pulmonary and Respiratory Medicine medicine.medical_specialty Adolescent Heart disease Heart Ventricles Transplantation Heterologous medicine Humans Transplantation Homologous Ventricular outflow tract Heart valve Child Retrospective Studies Bioprosthesis Heart Valve Prosthesis Implantation Pulmonary Valve Heart septal defect business.industry Heart Septal Defects Graft Survival Infant Newborn Infant General Medicine Prognosis medicine.disease Survival Analysis Surgery Transplantation Stenosis surgical procedures operative medicine.anatomical_structure Child Preschool Heart Valve Prosthesis Pulmonary valve Female Median body Cardiology and Cardiovascular Medicine business |
| Zdroj: | European Journal of Cardio-Thoracic Surgery. 17:624-630 |
| ISSN: | 1873-734X 1010-7940 |
| DOI: | 10.1016/s1010-7940(00)00414-0 |
| Popis: | Objective: The reconstruction of the RVOT in congenital heart disease often requires the implantation of a valved conduit. Although allografts are considered the conduit of choice their availability is limited and therefore xenografts are implanted as well. We compared the long-term durability of both grafts in the RVOT over a 25-year period. Methods: Between January 1974 and August 1999, 505 patients (median age 4.0 years, range 2 days‐31 years; median weight 14.5 kg, range 2.2‐76.6 kg; median body length 103 cm, range 48‐183 cm) with congenital malformations (PA 25.3%, TOF 14.5%, TOF 1 PA 2.4%, DORV 4.2%, TGA 1 PS 8.7%, TAC 24.8%, and other 20.2%) received their first valved conduit (174 xenografts: median diameter 14 mm, range 8‐27 mm; 331 allografts: median diameter 19 mm, range 8‐30 mm). Results: Follow-up is 3017 patient-years. The 10-year survival-probability for all patients. was 66% with a mean reoperation-free interval for conduit-exchange of 13.3 years (mean reoperation-free interval for allografts, 16.0 years; mean reoperation-free interval for xenograft, 10.3 years). One hundred and thirteen patients underwent a conduit-exchange, mostly due to conduit stenosis. Fourteen patients had a second exchange and three patients a third exchange. For patients with conduit diameters ,18 mm (na 235: allograft na 116, xenograft na 119; median age 9 months, range 0‐27.3 years), the mean reoperation-free interval was 11.2 years (mean interval allograft, 13.1 years; mean interval xenograft, 8.6 years, Pa 0:03). For conduit diameters $18 mm (na 270: allograft na 215, xenograft na 55, median age 7.4 years, range 0‐34.3 years) the mean interval from freedom of conduit exchange was 15.1 years (for allografts 14.1 years, for xenografts 12.5 years, P , 0:01). Comparing xenografts to allografts, we found no difference in patient survival probability (Pa 0:62). There was no significant difference between antibiotic (na 198) preserved vs. cryopreserved (na 133) allografts (Pa 0:06). Blood group compatibility of allografts to recipients had no significant influence on allograft function (Pa 0:42). The donors allograft origin, whether aortic or pulmonary valve, had also no significant influence on allograft long-term function (Pa 0:15). Conclusion: For the reconstruction of the right ventricular outflow tract (RVOT) allografts show significantly better long-term durability than xenografts regardless of the age at implantation and the diameter. q 2000 Published by Elsevier Science B.V. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|